Challenge status | Group | Lymphoid lesion score | In situ hybridization score | |
---|---|---|---|---|
PCV2a | PCV2b | |||
2a | 7 | 0.47 ± 0.35a,b | 0.71 ± 1.25b | 10.42 ± 5.22b |
8 | 0.51 ± 0.42a,b | 0.85 ± 1.46b | 11.14 ± 5.89b | |
11 | 0.71 ± 0.69a,b | 8.14 ± 6.06a | 10.7 ± 5.93b | |
13 | 1.57 ± 0.53c | 30.71 ± 10.96c | 0.0 ± 0.0a | |
2b | 1 | 0.53 ± 0.52a,b | 9.14 ± 6.56a | 2.0 ± 2.51a |
2 | 0.43 ± 0.53a,b | 7.28 ± 6.87a | 2.42 ± 3.1a | |
5 | 0.86 ± 0.48b | 8.42 ± 5.15a | 7.14 ± 4.14b | |
14 | 2.00 ± 0.81c | 0.0 ± 0.0b | 37.29 ± 8.96c | |
Non-challenged | 3 | 0.29 ± 0.49a | 5.71 ± 6.23a | 0.0 ± 0.0a |
4 | 0.23 ± 0.41a | 6.14 ± 5.49a | 0.0 ± 0.0a | |
6 | 0.31 ± 0.37a | 8.57 ± 6.07a | 0.0 ± 0.0a | |
9 | 0.35 ± 0.39a,b | 0.0 ± 0.0b | 8.85 ± 5.17b | |
10 | 0.41 ± 0.38a,b | 0.0 ± 0.0b | 7.14 ± 4.77b | |
12 | 0.43 ± 0.49a,b | 0.0 ± 0.0b | 9.14 ± 5.27b | |
15 | 0.0 ± 0.0a | 0.0 ± 0.0b | 0.0 ± 0.0a |